# Concerns about use of placebo control in clinical trials of Obinutuzumab β for aquaporin-4 antibody positive neuromyelitis optica spectrum disorder

Source: [Medical research : nature.com subject feeds](https://www.nature.com/articles/s41591-026-04781-0) · 2026-11-20 · Medicine
Page: https://themorning.science/story/concerns-about-use-of-placebo-control-in-clinical-trials-of-obinutuzumab-for-aqu-f17afb070bb81b95
Kind: other · Impact: medium

## In brief

- A Nature Medicine article raises concerns about the use of placebo control in clinical trials of obinutuzumab for aquaporin-4 antibody positive neuromyelitis optica spectrum disorder (NMOSD).
- The source feed provided only the headline and no summary, so the specific concerns raised are not available from the sources.

## Why it matters

Trial design choices, such as whether to use a placebo control, shape how treatment effects are judged in rare neuroimmune diseases like NMOSD.

## Coverage

- [Concerns about use of placebo control in clinical trials of Obinutuzumab β for aquaporin-4 antibody positive neuromyelitis optica spectrum disorder](https://www.nature.com/articles/s41591-026-04781-0) — Medical research : nature.com subject feeds, 2026-11-20

Tags: neuromyelitis optica, clinical trials, placebo control, obinutuzumab, neurology

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
